PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

Published:2014-12-22 Issue:3 Volume:28 Page:245-253
ISSN:1755-1471
Container-title:Pigment Cell & Melanoma Research
language:en
Short-container-title:Pigment Cell Melanoma Res

Author:

Madore Jason¹²,Vilain Ricardo E.¹²³,Menzies Alexander M.¹²,Kakavand Hojabr¹²,Wilmott James S.¹²,Hyman Jessica¹,Yearley Jennifer H.⁴,Kefford Richard F.¹²,Thompson John F.¹²,Long Georgina V.¹²,Hersey Peter¹²,Scolyer Richard A.¹²³

Affiliation:

1. Melanoma Institute Australia; Sydney NSW Australia

2. Sydney Medical School; The University of Sydney; Sydney NSW Australia

3. Tissue Pathology and Diagnostic Oncology; Royal Prince Alfred Hospital; Sydney NSW Australia

4. Merck & Co., Inc., Whitehouse Station; NJ USA

Funder

Cameron Fellowship through Melanoma Institute Australia

National Health and Medical Research Council

Cancer Institute New South Wales

Melanoma Foundation of the University of Sydney

Melanoma Institute Australia

Publisher

Wiley

Subject

Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pcmr.12340/fullpdf

Reference25 articles.

1. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma;Azimi;J. Clin. Oncol.,2012

2. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells;Blank;Cancer Res.,2004

3. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012

4. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization;Budczies;PLoS One,2012

Cited by 358 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discrepancy in PD-L1 expression between primary and metastatic tumors in two patients with recurrent cervical cancer;Gynecologic Oncology Reports;2024-10

2. Brightfield Multiplex Immunohistochemistry Assay for PD-L1 Evaluation in Challenging Melanoma Samples;Applied Immunohistochemistry & Molecular Morphology;2024-08-21

3. Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition;International Journal of Cancer;2024-07-20

4. The Feasibility and Diagnostic Adequacy of PD-L1 Expression Analysis Using the Cytoinclusion Technique in Bladder Cancer: A Prospective Single-Center Study;Journal of Clinical Medicine;2024-07-12

5. Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives;International Journal of Molecular Sciences;2024-06-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3